Indian Journal of Respiratory Care

IJRC Email      Register      Login

SEARCH WITHIN CONTENT

FIND ARTICLE

Volume / Issue

Online First

Archive
Volume  13 (2024)
Volume  12 (2023)
Volume  11 (2022)
Volume  10 (2021)
Volume  9 (2020)
Volume  8 (2019)
Volume  7 (2018)
Volume  6 (2017)
Volume  5 (2016)
Volume  4 (2015)
Volume  3 (2014)
Volume  2 (2013)
Volume  1 (2012)
Related articles

VOLUME 11 , ISSUE 2 ( April-June, 2022 ) > List of Articles

REVIEW ARTICLE

Potential Application of Probiotics in Attenuating the Link Between COVID-19 and Mucormycosis

Rohan Kumar Polamarasetty, P. Divya

Keywords : COVID-19, mucormycosis, probiotics

Citation Information : Polamarasetty RK, Divya P. Potential Application of Probiotics in Attenuating the Link Between COVID-19 and Mucormycosis. Indian J Respir Care 2022; 11 (2):95-100.

DOI: 10.4103/ijrc.ijrc_132_21

License: CC BY-NC-SA 4.0

Published Online: 06-12-2022

Copyright Statement:  Copyright © 2022; Indian Journal of Respiratory Care.


Abstract

COVID-19 has caused a significant amount of mortality and morbidity worldwide. It has paved the way for a plethora of complications including increase in the incidence of some previously rare diseases. Mucormycosis is one such opportunistic infection that has gained prominence in certain developing countries, especially India, during the pandemic. It is a life-threatening condition that requires to be managed promptly. Rampant use of steroids, immunomodulators, and antibiotics for the treatment of COVID-19 has led to hyperglycemia such as state, immunosuppression, and gut dysbiosis. All these conditions in addition to the local tissue damage mediated by the severe cytokine storm in the later stages of the disease are the key culprits for this upsurge. There is evidence promoting the potential use of probiotics for the prevention as well as the treatment of COVID-19. They boost and regulate the native immunity of the individual, simultaneously reducing the dependence on steroids and other immunomodulators. This can help prevent the development of opportunistic infections such as mucormycosis in COVID-19 patients. This article correlates the beneficial effects of probiotics in improving the individualÂ's immune status to halt the probable mechanism by which mucormycosis can develop in individuals with COVID-19.

HTML PDF Share
  1. Mucormycosis. World Health Organization. Available from: https://www.who.int/india/emergencies/coronavirus-disease-(covid-19)/mucormycosis. [Last accessed on 2021 Dec 19].
  2. Guideline for Management of Mucormycosis in COVID 19. Available from: https://dghs.gov.in/WriteReadData/News/202105171119301555988MucormycosismanagementinCovid-19.pdf. [Last accessed2021 Dec 19].
  3. Balachandar V, Mahalaxmi I, Subramaniam M, Kaavya J, Senthil Kumar N, Laldinmawii G, et al. Follow-up studies in COVID-19 recovered patients - Is it mandatory? Sci Total Environ 2020;729:139021.
  4. Mahalaxmi I, Jayaramayya K, Venkatesan D, Subramaniam MD, Renu K, Vijayakumar P, et al. Mucormycosis: An opportunistic pathogen during COVID-19. Environ Res 2021;201:111643.
  5. Moona AA, Islam MR. Mucormycosis or black fungus is a new fright in India during covid-19 pandemic: Associated risk factors and actionable items. Public Health Pract (Oxf) 2021;2:100153. [doi: 10.1016/j.puhip.2021.100153]. Epub 2021 Jun 21. PMID: 34179859; PMCID: PMC8215889.
  6. Caccuri F, Bugatti A, Zani A, De Palma A, Di Silvestre D, Manocha E, et al. SARS CoV 2 infection remodels the phenotype and promotes angiogenesis of primary human lung endothelial cells. Microorganisms 2021;9:1438.
  7. Jafarzadeh A, Jafarzadeh S, Nozari P, Mokhtari P, Nemati M. Lymphopenia an important immunological abnormality in patients with COVID 19: Possible mechanisms. Scand J Immunol 2021;93:e12967.
  8. Pal R, Singh B, Bhadada SK, Banerjee M, Bhogal RS, Hage N, et al. COVID-19-associated mucormycosis: An updated systematic review of literature. Mycoses 2021;64:1452-9.
  9. John TM, Jacob CN, Kontoyiannis DP. When uncontrolled diabetes mellitus and severe COVID-19 Converge: The perfect storm for mucormycosis. J Fungi (Basel) 2021;7:298.
  10. Perricone C, Bartoloni E, Bursi R, Cafaro G, Guidelli GM, Shoenfeld Y, et al. COVID 19 as part of the hyperferritinemic syndromes: The role of iron depletion therapy. Immunol Res 2020;68:213-24.
  11. Malhotra N, Bajwa SJ, Joshi M, Mehdiratta L, Kurdi M. Second wave of COVID 19 pandemic and the surge of mucormycosis: Lessons learnt and future preparedness: Indian Society of Anaesthesiologists (ISA National) Advisory and Position Statement. Indian J Anaesth 2021;65:427-33.
  12. Bhogireddy R, Krishnamurthy V, Jabaris SS, Pullaiah CP, Manohar S. Is Mucormycosis an inevitable complication of COVID 19 in India? Braz J Infect Dis 2021;25:101597.
  13. Mucormycosis: A Brief Review. Available from: http://www.dmer.org/new/Mucormycosis_A_Brief_Review.pdf [Last accessed on 2021 May 26].
  14. Guidelines for the Evaluation of Probiotics in Food. https://www. who.int/foodsafety/fs_management/en/probiotic_guidelines.pdf. [Last accessed 2021 Dec 19].
  15. Bustamante M, Oomah BD, Oliveira WP, Burgos-Díaz C, Rubilar M, Shene C. Probiotics and prebiotics potential for the care of skin, female urogenital tract, and respiratory tract. Folia Microbiol (Praha) 2020;65:245-64.
  16. Hauptmann M, Schaible UE. Linking microbiota and respiratory disease. FEBS Lett 2016;590:3721-38.
  17. Rajilić-Stojanović M, de Vos WM. The first 1000 cultured species of the human gastrointestinal microbiota. FEMS Microbiol Rev 2014;38:996-1047.
  18. Barcik W, Boutin RC, Sokolowska M, Finlay BB. The role of lung and gut microbiota in the pathology of asthma. Immunity 2020;52:241-55.
  19. Chehrazi N, Cipriano LE, Enns EA. Dynamics of drug resistance: Optimal control of an infectious disease. Oper Res 2019;67:599-904.
  20. Din AU, Mazhar M, Waseem M, Ahmad W, Bibi A, Hassan A, et al. SARS-CoV-2 microbiome dysbiosis linked disorders and possible probiotics role. Biomed Pharmacother 2021;133:110947.
  21. Wang H, Liu JS, Peng SH, Deng XY, Zhu DM, Javidiparsijani S, et al. Gut lung crosstalk in pulmonary involvement with inflammatory bowel diseases. World J Gastroenterol 2013;19:6794 804.
  22. Olaimat AN, Aolymat I, Al-Holy M, Ayyash M, Abu Ghoush M, Al-Nabulsi AA, et al. The potential application of probiotics and prebiotics for the prevention and treatment of covid-19. npj Science of Food. 2020;4:17.
  23. Dang AT, Marsland BJ. Microbes, metabolites, and the gut lung axis. Mucosal Immunol 2019;12:843-50.
  24. Hufnagl K, Pali Schöll I, Roth Walter F, Jensen Jarolim E. Dysbiosis of the gut and lung microbiome has a role in asthma. Semin Immunopathol 2020;42:75-93.
  25. Mortaz E, Bezemer G, Alipoor SD, Varahram M, Mumby S, Folkerts G, et al. Nutritional impact and its potential consequences on COVID
  26. Front Nutr 2021;8:698617.
  27. Smyk W, Janik MK, Portincasa P, Milkiewicz P, Lammert F, Krawczyk M. Covid-19: Focus on the lungs but do not forget the gastrointestinal tract. European Journal of Clinical Investigation. 2020;50: e13276.
  28. Sundararaman A, Ray M, Ravindra PV, Halami PM. Role of probiotics to combat viral infections with emphasis on COVID 19. Appl Microbiol Biotechnol 2020;104:8089-104.
  29. Fanos V, Pintus MC, Pintus R, Marcialis MA. Lung microbiota in the acute respiratory disease: from coronavirus to metabolomics. Journal of Pediatric and Neonatal Individualized Medicine. 2020;9:e090139.
  30. Lehtoranta L, Pitkäranta A, Korpela R. Probiotics in respiratory virus infections. Eur J Clin Microbiol Infect Dis 2014;33:1289-302.
  31. Mortaz E, Adcock IM, Folkerts G, Barnes PJ, Paul Vos A, Garssen J. Probiotics in the management of lung diseases. Mediators Inflamm 2013;2013:751068.
  32. Chong HX, Yusoff NA, Hor YY, Lew LC, Jaafar MH, Choi, et al. Lactobacillus plantarum DR7 improved upper respiratory tract infections via enhancing immune and inflammatory parameters: A randomized, double blind, placebo controlled study. J Dairy Sci 2019;102:4783-97.
  33. Shoaib A, Xin L, Xin Y. Oral administration of Lactobacillus acidophilus alleviates exacerbations in Pseudomonas aeruginosa and Staphylococcus aureus pulmonary infections. Pak J Pharm Sci 2019;32:1621-30.
  34. Namba K, Hatano M, Yaeshima T, Takase M, Suzuki K. Effects of Bifidobacterium longum BB536 administration on influenza infection, influenza vaccine antibody titer, and cell mediated immunity in the elderly. Biosci Biotechnol Biochem 2010;74:939-45.
  35. Ye Q, Wang B, Mao J. The pathogenesis and treatment of the ‘Cytokine Storm’ in COVID 19. J Infect 2020;80:607-13.
  36. Khaled JM. Probiotics, prebiotics, and COVID 19 infection: A review article. Saudi J Biol Sci 2021;28:865-9.
  37. Dhar D, Mohanty A. Gut microbiota and Covid 19 possible link and implications. Virus Res 2020;285:198018.
  38. Yan F, Polk DB. Probiotics and immune health. Curr Opin Gastroenterol 2011;27:496 501.
  39. Aggarwal S, Gollapudi S, Gupta S. Increased TNF alpha induced apoptosis in lymphocytes from aged humans: Changes in TNF alpha receptor expression and activation of caspases. J Immunol 1999;162:2154-61.
  40. Chan JF, Zhang AJ, Yuan S, Poon VK, Chan CC, Lee AC, et al. Simulation of the clinical and pathological manifestations of coronavirus disease 2019 (COVID 19) in a golden syrian hamster model: Implications for disease pathogenesis and transmissibility. Clin Infect Dis 2020;71:2428-46.
  41. You B, Ravaud A, Canivet A, Ganem G, Giraud P, Guimbaud R, et al. The official French guidelines to protect patients with cancer against SARS CoV 2 infection. Lancet Oncol 2020;21:619-21.
  42. Fischer K, Hoffmann P, Voelkl S, Meidenbauer N, Ammer J, Edinger M, et al. Inhibitory effect of tumor cell derived lactic acid on human T cells. Blood 2007;109:3812-9.
  43. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020;382:1708-20.
  44. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497-506.
  45. Pandiar D, Kumar NS, Anand R, Kamboj M, Narwal A, Shameena PM. Does COVID 19 generate a milieu for propagation of mucormycosis? Med Hypotheses 2021;152:110613.
  46. Yang JK, Feng Y, Yuan MY, Yuan SY, Fu HJ, Wu BY, et al. Plasma glucose levels and diabetes are independent predictors for mortality and morbidity in patients with SARS. Diabet Med 2006;23:623 8.
  47. Yang JK, Lin SS, Ji XJ, Guo LM. Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes. Acta Diabetol 2010;47:193-9.
  48. Xu H, Zhong L, Deng J, Peng J, Dan H, Zeng X, et al. High expression of ACE2 receptor of 2019 nCoV on the epithelial cells of oral mucosa. Int J Oral Sci 2020;12:8.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.